Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease

European Heart Journal

Volumn 34, Issue 45, 2013, Pages

  Nordestgaard, Børge G ^a   Chapman, M John ^b   Humphries, Steve E ^c   Ginsberg, Henry N ^d   Masana, Luis ^e   Descamps, Olivier S ^f   Wiklund, Olov ^g   Hegele, Robert A ^h   Raal, Frederick J ⁱ   Defesche, Joep C ^j   Wiegman, Albert ^j   Santos, Raul D ^k   Watts, Gerald F ^l   Parhofer, Klaus G ^m   Hovingh, G Kees ^j   Kovanen, Petri T ⁿ   Boileau, Catherine ^o   Averna, Maurizio ^p   Borén, Jan ^q   Bruckert, Eric ^b   Catapano, Alberico L ^r   Kuivenhoven, Jan Albert ^s   Pajukanta, Päivi ^t   Ray, Kausik ^u   Stalenhoef, Anton F H ^v   Stroes, Erik ^j   Taskinen, Marja Riitta ^w   Tybjærg Hansen, Anne ^x   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Howard Hughes Medical Institute   (United States)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f Hospital de Jolimont   (Belgium)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ WIHURI RESEARCH INSTITUTE   (Finland)

^o INSERM   (France)

^p UNIVERSITY OF PALERMO   (Italy)

^q UNIVERSITY OF GOTHENBURG   (Sweden)

^r UNIVERSITY OF MILAN   (Italy)

^s UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^w BIOMEDICUM HELSINKI   (Finland)

^x International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

more..

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low density lipoprotein

Indexed keywords

CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ERROR; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETICS; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH; XANTHOMA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL; CORONARY HEART DISEASE; LOW-DENSITY LIPOPROTEIN;

ADULT; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EARLY DIAGNOSIS; FEMALE; FORECASTING; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; PEDIGREE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84890461947     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht273     Document Type: Article

References (56)

1. Goldstein JK, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds), The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 2863-2913.
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol 2004;160:407-420.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 2008;337:a2423.
4. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168: 1-14.
5. World Health Organization. World Healths Statistics 2012. Internet. http://www.who.int/gho/publications/world-health-statistics/2012/en/(9 October 2012).
6. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF,Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
7. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
8. Minhas R, Humphries SE, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M, Barbir M, Lucassen A, Parke A, Wierzbicki A, Williams H, Wray R, Shaw E, Turnbull N, DeMott K, Kathoria M, Nunes V, Nherera L, Ritchie G. UK NICE Guideline on Identification and Management of FH (CG71). Internet. http://www.nice.org.uk/CG071 (30 March 2013).
9. Heiberg A, Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis.A study of 132 kindreds. Clin Genet 1976;9:203-233.
10. Benn M,Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97:3956-3964.
11. Neil HA, Hammond T, Huxley R, MatthewsDR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
12. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-112.
13. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 2008;6:567-581.
14. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795-1803.
15. Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, Orengo CA, Martin AC, Celli J, Humphries SE. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012;76:387-401.
16. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262-268.
17. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, Martinez de Esteban JP, Ferrando J, Zabala S, Almagro F, Gimeno JA, Masana L, Pocovi M. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008; 102:1187-1193. 1193.
18. Palacios L, Grandoso L, Cuevas N, Olano-Martin E, Martinez A, Tejedor D, Stef M. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012;221:137-142.
19. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol 2003;23:335-338.
20. Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJ. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: A crosssectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012;5:354-359.
21. Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, Neil HA, Humphries SE. Development of sensitive and specific age-And gender-specific lowdensity lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008;46: 791-803.
22. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
23. Jarauta E, Junyent M, Gilabert R, Plana N, Mateo-Gallego R, de GE, Cenarro A, Nunez I, Coll B, Masana L, Ros E, Civeira F. Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis 2009;204:345-347.
24. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A,Watts GF. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-1361.
25. Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte Op Reimer WJ, Vrints C,Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1-68.
26. WattsGF, SullivanDR, Poplawski N, van BF,Hamilton-Craig I, Clifton PM, O'Brien R, BishopW, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O'Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S, Trent R. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler Suppl 2011;12:221-263.
27. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990;335:1360-1363.
28. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20: 522-528.
29. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 2331-2339.
30. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F,Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31: 2844-2853.
31. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van LennepHW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482-490.
32. Stefanutti C. Treatment of severe genetic dyslipidemia: where are we going?. Ther Apher Dial 2013;17:122-123.
33. Stefanutti C, Morozzi C, Di GS. Italian multicenter study on low-density lipoprotein apheresisWorking Group 2009 survey. Ther Apher Dial 2013;17:169-178.
34. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kalsch H, Muhleisen TW, Nothen MM, Cupples LA, Caslake M, Di AE, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503-512.
35. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, CromwellWC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S1-S8.
36. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC Jr, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56: e50-103.
37. Kusters DM, de BC, Widhalm K, Guardamagna O, Bratina N, Ose L, Wiegman A. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child 2012;97: 272-276.
38. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:3332-3337.
39. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009;17:720-721.
40. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009;50(Suppl):S172-S177.
41. Broekhuizen K, Jelsma GJ, van PoppelNM, Koppes LL, Brug J, vanMW. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with Familial Hypercholesterolemiä BMC Public Health 2012;12:348.
42. Weisweiler P. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia. Metabolism 1989;38:271-274.
43. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S18-S29.
44. Kucukcongar A, Yenicesu I, Tumer L, Kasapkara CS, Ezgu FS, Pasaoglu O, Demirtas C, Celik B, Dilsiz G, Hasanoglu A. Apheresis-inducible cytokine pattern change in children with homozygous familial hypercholesterolemia. Transfus Apher Sci 2013;48:391-396.
45. Fernandez-Fuertes LF, Tapia MM, Nieves PI, Novoa Mogollon FJ, Diaz CJ. Lowdensity lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia. Ther Apher Dial 2010;14:484-485.
46. Stefanutti C, Di GS, Vivenzio A, Colloridi V, Bosco G, Berni A, Rabbone I, Cerutti F, Bertolini S. Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr 2001;90:694-701.
47. Stefanutti C, Vivenzio A, Ferraro PM, Morozzi C, Belotherkovsky D. Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine 2011;56:835-841.
48. Schuff-Werner P, Fenger S, Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 2012;7:7-14.
49. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA. A systematic reviewand meta-Analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007;27:1803-1810.
50. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-Analysis. Atherosclerosis 2007;195:339-347.
51. Wiegman A, Hutten BA, de GE, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 2004;292:331-337.
52. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de GE, Wijburg FA, Kastelein JJ, Hutten BA. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116:664-668.
53. Marks D,Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303.
54. Nherera L, Calvert NW, Demott K, Humphries SE, Neil HA, Minhas R, Thorogood M. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26:529-536.
55. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic costeffectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97:1175-1181.
56. Nherera LM. Saving lives, saving families: the health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH). Economics Chapter: Estimating the benefits from treatment and increasing the implementation of cascading screening. Internet. http://heartuk.org.uk/ files/uploads/documents/HUK-HealthEconomics-FINAL2012-2702.pdf (17 December 2012).